The recent discovery of classic AD pathology blood biomarkers, namely plasma Aβ42/40 ratios, phosphorylated tau (p-tau), and the neurodegeneration biomarker neurofilament light polypeptide (NEFL), raises the possibility of establishing alternative, highly sensitive/specific, and less invasive blood-based diagnostic panels of proteins reflecting the pathological pathways underlying the development of dementia [14,15,16,17,18,19,20,21]. The gene discussed is MAPT; the disease is Alzheimer disease.